Fermer le menu

 

Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates

 

  • First Close of Series B financing raises €10 million
  • Meiji Seika Pharma Co., Ltd joins as new international investor
  • Proceeds will accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates

 

 

Read the press release

Plus d'infos